You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽升藥業(300485.SZ)與併購基金向普濟醫藥投資合計1億元
格隆匯 08-15 21:19

格隆匯8月15日丨賽升藥業(300485.SZ)公佈,公司於近日與北京亦莊生物醫藥併購投資中心(有限合夥)(以下簡稱“併購基金”)、杭州普濟醫藥技術開發有限公司(以下簡稱“普濟醫藥”)及劉金明、劉天航簽署了《附條件生效的股權認購及受讓協議》,公司與併購基金擬以現金出資方式,整體向普濟醫藥合計投資1億元人民幣。其中公司擬以人民幣5000萬元出資認購普濟醫藥新增註冊資本1884.5萬元,併購基金擬以人民幣5000萬元出資認購普濟醫藥新增註冊資本1884.5萬元。增資後公司持有普濟醫藥27.78%股權,併購基金持有普濟醫藥27.78%股權。

生物蛋白膠行業在我國尚屬於起步發展階段,對於生物蛋白膠升級為生物製品,行業門檻較高。普濟醫藥成立於1995年,主要從事醫用止血用生物蛋白膠的研發和生產,是浙江省唯一一個動物血源型生物藥品製造企業。其產品豬源纖維蛋白粘合劑於2004獲得械字號註冊批文,根據國家局要求於2008年進入藥品轉型,2013年獲得藥品生產許可證及藥字號註冊批文,均已成功進入市場銷售。目前普濟醫藥生產產品是豬源纖維蛋白粘合劑和配套的一次性使用生物蛋白膠配置器(二類器械)。在可吸收止血材料中纖維蛋白類生物相容性好,無毒無刺激,不會產生粘連溶血現象,具有極高技術優勢。同時,相比人纖維蛋白粘合劑,動物血液原料來源豐富,經過處理既可降低成本,又能排除人體血源性疾病的感染機會。

作為本次投資方之一,賽升藥業主要銷售產品中包括動物提取生物生化藥物,公司生物大分子研發平台的分離純化技術國內領先。本次公司與普濟醫藥的合作可充分結合豬源纖維蛋白粘合劑的生產工藝,為普濟醫藥提供GMP整改、工藝優化等服務,充分發揮產業協同效應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account